Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346. The study will run in Canada and is expected to conclude in December 2018.
Input Will Drive Trial Design for Lead Cancer Stem Cell-Targeting Program
September 10, 2013 - Veristat, a leading, Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem, Inc. (NASDAQ: VSTM).